Novo Nordisk Shares Likely to Fall at Open, But Less Than in U.S. Session -- Market Talk
Dow Jones2026/08/05 07:010700 GMT - Novo Nordisk shares are expected to come under pressure in Europe this morning, but to a lesser degree than the 6% drop in U.S. trading yesterday, Jyske Bank's Henrik Hallengreen Laustsen writes. The company significantly beat estimates in the second quarter and raised its outlook more than expected. Sales and earnings were both above expectations in the quarter, driven by Ozempic, while the Wegovy pill performed largely as forecast. Consensus estimates might be increased by approximately 3% if expectations are raised to the midpoint of the new guidance, he adds. However, a study of its CagriSema drug showed that the product is no better than Eli Lilly's Mounjaro in diabetes, which could pressure CagriSema estimates and thus Novo's long-term growth profile, which remains one of investors' biggest concerns. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
August 05, 2026 03:01 ET (07:01 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Community Reacts As Pundit Claims XRP Will Be Priced At $2,953 By Q2 2027
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Crypto prices
More
